1. Home
  2. FOLD vs TBBK Comparison

FOLD vs TBBK Comparison

Compare FOLD & TBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • TBBK
  • Stock Information
  • Founded
  • FOLD 2002
  • TBBK 1999
  • Country
  • FOLD United States
  • TBBK United States
  • Employees
  • FOLD N/A
  • TBBK 757
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • TBBK Major Banks
  • Sector
  • FOLD Health Care
  • TBBK Finance
  • Exchange
  • FOLD Nasdaq
  • TBBK Nasdaq
  • Market Cap
  • FOLD 2.9B
  • TBBK 2.6B
  • IPO Year
  • FOLD 2007
  • TBBK 2004
  • Fundamental
  • Price
  • FOLD $9.80
  • TBBK $53.31
  • Analyst Decision
  • FOLD Strong Buy
  • TBBK Buy
  • Analyst Count
  • FOLD 8
  • TBBK 3
  • Target Price
  • FOLD $16.71
  • TBBK $55.00
  • AVG Volume (30 Days)
  • FOLD 2.8M
  • TBBK 491.1K
  • Earning Date
  • FOLD 11-06-2024
  • TBBK 01-23-2025
  • Dividend Yield
  • FOLD N/A
  • TBBK N/A
  • EPS Growth
  • FOLD N/A
  • TBBK 16.50
  • EPS
  • FOLD N/A
  • TBBK 3.95
  • Revenue
  • FOLD $493,671,000.00
  • TBBK $472,068,000.00
  • Revenue This Year
  • FOLD $34.30
  • TBBK N/A
  • Revenue Next Year
  • FOLD $21.78
  • TBBK $7.93
  • P/E Ratio
  • FOLD N/A
  • TBBK $13.50
  • Revenue Growth
  • FOLD 32.58
  • TBBK 6.73
  • 52 Week Low
  • FOLD $9.02
  • TBBK $29.92
  • 52 Week High
  • FOLD $14.57
  • TBBK $61.17
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 45.87
  • TBBK 43.27
  • Support Level
  • FOLD $9.41
  • TBBK $55.25
  • Resistance Level
  • FOLD $9.99
  • TBBK $57.38
  • Average True Range (ATR)
  • FOLD 0.35
  • TBBK 1.98
  • MACD
  • FOLD 0.03
  • TBBK -0.61
  • Stochastic Oscillator
  • FOLD 48.15
  • TBBK 24.74

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company, through its subsidiary it is engaged in specialty lending namely securities-backed lines of credit, vehicle fleet and another equipment leasing, Small Business Administration lending, insurance policy cash value-backed lines of credit and commercial mortgage-backed loans, generated for sale into commercial mortgage-backed securities markets through securitizations. The company deposits and non-interest income are generated in the payments business which consists of issuing, acquiring, and automated clearing house accounts.

Share on Social Networks: